Loading...
Vi vill gärna att du blir en del av vår gemenskap. Gå med i vår Discord för att komma i kontakt med oss och andra medlemmar!
- Ticker
- MVIR.ST
- Price
- 1.61
- Stock movement down
- -0.10 (-5.03%)
- Company name
- Medivir AB
- Exchange
- (ST ,
- Currency
- SEK )
- Sector
- Healthcare >Biotechnology
- Marknadsvärde
- 207.74M
- Ent-värde
- -
- Pris/omsättning
- -
- Pris/bok
- -
- Direktavkastning
- -
- Utdelningens tillväxt
- -
- Tillväxt år
- -
- FCF-utbetalning
- -
- Efterföljande P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-tillväxt
- -
- 1 års avkastning
- -38.68%
- 3 års avkastning
- -38.00%
- 5 års avkastning
- -31.30%
- 10 års avkastning
- -30.66%
Senast uppdaterad: 2025-09-17
UTDELNING
MVIR.ST Betalar inte utdelning
UTVÄRDERING
Värderingsvillkor
Loading...
Data om värderingsgrad
| Efterföljande P/E | - |
| Pris till OCF | - |
| Pris till FCF | - |
| Pris till EBITDA | - |
| EV i förhållande till EBITDA | - |
Värdering (Försäljning/Bokfört värde)
Loading...
Värderingsdata (försäljning/bokfört värde)
| Pris till omsättning | - |
| Pris till eget kapital | - |
| EV i förhållande till försäljning | - |
EKONOMI
INFORMATION OM AKTIER
Aktiediagram
Loading...
Uppgifter om aktiekurs
| Öppning | 1.97 |
| Dagens högsta | 2.00 |
| Daglig låg | 1.85 |
| Daglig volym | 182K |
| Den högsta någonsin | 190.06 |
| 1 års analytikeruppskattning | 20.71 |
| Beta | -0.23 |
| EPS (TTM) | - |
| Utdelning per aktie | - |
| Ex-div datum | - |
| Nästa datum för resultatpresentation | 6 Nov 2025 |
Potential på nackdelen
Loading...
Negativa potentiella data
| MVIR.ST | S&P500 | |
| Nuvarande prisfall från toppnotering | -99.03% | -1.06% |
| Högsta prisfallet | -99.35% | -56.47% |
| Datum för högsta fall | 7 Apr 2025 | 9 Mar 2009 |
| Genomsnittligt fall från topp | -75.66% | -10.99% |
| Genomsnittlig tid till ny topp | 407 days | 12 days |
| Maxtid till ny topp | 6471 days | 1805 days |
UPPLYSNINGAR OM FÖRETAG
Marknadsvärde
207.74M
Kategori av marknadsvärde
Small-cap
Beskrivning: __________
Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors, as well as USP-1/TNG348, USP-7, and MBLI/MET-X, which completed preclinical trials for treating cancer and infection. It has a clinical trial collaboration and supply agreement with Eisai to evaluate fostrox, a liver-targeted treatment, in combination with lenvatinib for the treatment of liver cancer. The company was incorporated in 1987 and is based in Huddinge, Sweden.
Anställda
10
Webbplats
Investerarrelationer
-
SEC-inlämningar
Verkställande direktör
Land
Sweden
By
Typ av aktie
-
CCC-status
-
Utdelningsfrekvens
-
EVENEMANG OCH PRESENTATIONER
EvenemangPresentationer
Loading...
FÖRSTÅ VERKSAMHETEN
Loading...
NYHETER OM FÖRETAGET
Alla nyheterPressmeddelanden
Medivir AB (STU:MVR0) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (STU:MVR0) reports promising clinical developments and patent extensions, while navigating funding hurdles to sustain its innovative pipeline.
22 augusti 2025
STOCKHOLM, SE / ACCESS Newswire / August 20, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusin...
20 augusti 2025
The European market has shown mixed performance recently, with the pan-European STOXX Europe 600 Index remaining flat over a four-day period, while major indexes such as France's CAC 40 and Italy's FT...
9 juli 2025
As European markets continue to navigate a landscape marked by mixed performances and hopes for easing trade tensions, investors are increasingly seeking opportunities in less conventional areas. Penn...
15 maj 2025
Amid escalating trade tensions and the lowest consumer sentiment in nearly three years, European markets have experienced notable volatility. Despite these challenges, the concept of penny stocks rema...
16 april 2025
As European markets navigate the complexities of U.S. trade tariffs and monetary policy uncertainties, the pan-European STOXX Europe 600 Index recently saw a slight decline. Despite these challenges, ...
18 mars 2025
Medivir AB (FRA:MVR0) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Medivir AB (FRA:MVR0) reports significant progress in liver cancer treatment development, despite facing increased clinical costs and market competition.
19 februari 2025
Global markets have recently experienced mixed performances, with major stock indexes showing a combination of gains and declines as the year closed out. For investors looking beyond traditional blue-...
6 januari 2025